장기 보존 시장 : 제품별, 보존 방법별, 장기 유형별, 용도별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Organ Preservation Market is projected to grow by USD 432.88 million at a CAGR of 7.42% by 2032.

The organ preservation market is moving from a narrow focus on static cold storage toward a broader ecosystem of preservation solutions, machine perfusion platforms, transport systems, and data-enabled transplant logistics. This shift is driven by the global shortage of transplantable organs: the Global Observatory on Donation and Transplantation has reported roughly 157,000 solid organ transplants worldwide in 2022, meeting less than 10% of estimated global need.

For manufacturers, transplant centers, and procurement organizations, organ preservation is now a strategic capability rather than a back-end clinical step. Demand is rising for hypothermic machine perfusion, normothermic machine perfusion, advanced preservation fluids, sterile disposables, and monitoring tools that help extend preservation windows, assess organ viability, and reduce discard rates across kidney, liver, heart, lung, and pancreas transplantation.

Transformative Shifts in the Organ Preservation Landscape

The organ preservation landscape is being reshaped by the convergence of donor scarcity, expanding transplant indications, and stronger clinical evidence for dynamic preservation. Static cold storage remains widely used because it is cost-effective and operationally simple, but machine perfusion is gaining traction where centers seek better viability assessment and improved outcomes for marginal, older, or donation-after-circulatory-death organs.

Transformative growth is also coming from integrated transplant logistics. Organ transport is time-sensitive, highly regulated, and increasingly dependent on temperature assurance, chain-of-custody documentation, real-time tracking, and cross-border coordination. As transplant networks pursue higher utilization of donated organs, preservation suppliers that combine hardware, consumables, clinical services, and analytics are best positioned for long-term competitiveness.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the organ preservation market across donor-recipient matching, viability scoring, perfusion parameter interpretation, imaging review, and logistics optimization. AI-enabled decision support can help identify patterns in perfusate biomarkers, hemodynamics, oxygen consumption, temperature stability, and transport timing that may not be visible through conventional assessment alone.

The cumulative impact is expected to be operational as much as clinical. AI can support route planning, predict preservation-time risk, reduce delays, and improve quality control in organ transport. However, adoption depends on validated datasets, regulatory oversight, explainable models, cybersecurity, and clinician governance, because allocation and organ acceptance decisions carry direct ethical and patient-safety implications.

Key Regional Insights

North America leads in advanced organ preservation adoption due to mature transplant infrastructure, strong organ procurement organization networks, and high procedure volumes. In the United States, federal transplant data show more than 46,000 organ transplants were performed in 2023, reinforcing demand for preservation fluids, perfusion devices, and logistics platforms, while Canada continues to strengthen national coordination through Canadian Blood Services and provincial transplant programs.

Europe benefits from established cross-border collaboration through frameworks such as Eurotransplant and Scandiatransplant, alongside European quality and safety rules for human organs that support standardized procurement, preservation, and traceability. Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in donation governance, transplant capacity, and high-acuity hospital infrastructure, creating demand for hypothermic machine perfusion, normothermic perfusion, and advanced preservation media.

Latin America is anchored by Brazil's large public transplant system and growing regional attention to organ donation coordination, though infrastructure disparities continue to shape access. The Middle East is advancing through hospital modernization and national transplant programs in Saudi Arabia, the United Arab Emirates, and Qatar, while Africa remains underpenetrated, with South Africa representing one of the region's more developed transplant markets and many countries still limited by donor registration, specialist workforce, and cold-chain constraints.

Key Group Insights

The European Union supports organ preservation demand through harmonized safety expectations, cross-border exchange mechanisms, and high clinical adoption of advanced transplant technologies. G7 countries collectively represent a major premium market because they combine high healthcare spending, sophisticated transplant centers, established reimbursement pathways, and strong regulatory oversight for medical devices, biologics, and transplant logistics.

BRICS countries are increasingly important for volume expansion as Brazil, Russia, India, China, and South Africa develop transplant infrastructure, national donation systems, and domestic medical technology capabilities. ASEAN shows uneven but rising potential, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines at different stages of transplant system maturity, creating opportunities for scalable preservation solutions suited to diverse hospital and logistics environments.

GCC countries are investing in specialized transplant centers, tertiary care modernization, and regional medical service capabilities, supporting demand for reliable preservation fluids, perfusion systems, and temperature-controlled logistics. NATO-member markets add demand resilience through strong emergency preparedness, healthcare security planning, regulated cold-chain standards, and advanced transport coordination across member healthcare systems.

Key Country Insights

The United States remains the most commercially attractive country for organ preservation solutions because of its large transplant volume, dense procurement network, and openness to innovation in machine perfusion. Canada follows with coordinated provincial systems and national data collaboration, while Mexico is expanding transplant access but remains constrained by uneven infrastructure and donation-system variability. Brazil is Latin America's leading transplant market, supported by a national public health framework and high kidney and liver transplant activity.

In Europe, the United Kingdom, Germany, France, Italy, and Spain represent advanced demand centers for preservation solutions, machine perfusion devices, and transplant logistics, with Spain recognized globally for high deceased donation performance under a coordinated national model. Russia has transplant capabilities concentrated in major urban centers, creating demand primarily around specialized hospitals and regional referral networks.

In Asia-Pacific, China is scaling regulated donation and transplantation through national oversight and hospital accreditation, while India has large unmet transplant need driven by chronic kidney and liver disease and variable state-level infrastructure. Japan faces aging demographics and historically low deceased donor rates, making organ utilization and preservation quality especially important. Australia maintains strong donation governance and national coordination, and South Korea supports high-acuity transplant services with advanced hospital infrastructure, specialist expertise, and strong adoption potential for dynamic organ preservation technologies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated differentiation. Preservation fluid suppliers, perfusion device manufacturers, and transplant logistics providers need evidence showing improved organ utilization, reduced complications, longer preservation windows, stronger viability assessment, or better cost-effectiveness compared with conventional static cold storage.

Companies should also invest in service models that reduce friction for transplant programs, including clinical training, 24/7 technical support, disposables availability, remote monitoring, preventive maintenance, and quality documentation. Strategic partnerships with organ procurement organizations, transplant societies, hospital networks, and cold-chain logistics providers will be critical to scaling adoption while meeting regulatory, ethical, and clinical governance requirements.

Research Methodology

This executive summary is built on secondary research from recognized transplant and healthcare sources, including the Global Observatory on Donation and Transplantation, WHO-linked datasets, national transplant registries, organ procurement authorities, clinical society guidance, and public regulatory information. Market interpretation is triangulated with published evidence on static cold storage, hypothermic machine perfusion, normothermic machine perfusion, preservation solutions, and organ transport.

The research approach emphasizes verified indicators such as transplant volumes, donation frameworks, hospital infrastructure, regulatory maturity, reimbursement conditions, cold-chain readiness, and adoption of advanced preservation technologies. Insights are synthesized to identify demand drivers, regional differences, group-level opportunities, country-level patterns, and strategic implications for companies operating in the organ preservation market.

Conclusion

Organ preservation is becoming a central lever for improving transplant access, reducing organ discard, and increasing the clinical value of every donated organ. The market is supported by durable fundamentals: global organ shortages, rising chronic disease burden, aging populations, and continued investment in transplant infrastructure.

The next phase of development will favor organizations that combine proven preservation science with device reliability, logistics intelligence, regulatory discipline, and clinician-friendly workflows. As machine perfusion, AI-enabled monitoring, and cross-border transplant coordination mature, organ preservation will remain a high-impact segment of the global transplant ecosystem.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Organ Preservation Market, by Offerings

• 7.1. Devices
  • 7.1.1. Accessories
  • 7.1.2. Perfusion Systems
• 7.2. Services
  • 7.2.1. Training & Maintenance
  • 7.2.2. Transplant Coordination
• 7.3. Solutions
  • 7.3.1. Data Management & Analysis
  • 7.3.2. Decision Support & Communication
  • 7.3.3. Tracking & Monitoring

8. Organ Preservation Market, by Preservation Method

• 8.1. Hypothermic Machine Perfusion
• 8.2. Normothermic Machine Perfusion
• 8.3. Static Cold Storage

9. Organ Preservation Market, by Organ Type

• 9.1. Heart
• 9.2. Kidney
• 9.3. Liver
• 9.4. Lung
• 9.5. Pancreas

10. Organ Preservation Market, by Application

• 10.1. Research & Development
• 10.2. Transplantation
• 10.3. Transportation

11. Organ Preservation Market, by End User

• 11.1. Hospitals
• 11.2. Organ Banks
• 11.3. Research Institutes
• 11.4. Transplant Centers

12. Organ Preservation Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Organ Preservation Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Organ Preservation Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. 21st Century Medicine
• 16.2. Artivion Inc
• 16.3. BioLife Solutions Inc
• 16.4. Bridge to Life Ltd
• 16.5. Carnamedica
• 16.6. Dr. Franz Kohler Chemie GmbH
• 16.7. EBERS Medical Technology SL
• 16.8. Essential Pharmaceuticals LLC
• 16.9. Getinge AB
• 16.10. Global Transplant Solutions
• 16.11. Hemarina SA
• 16.12. iCoat Medical AB
• 16.13. IGL Transplantation Services
• 16.14. Lifeline Scientific Inc
• 16.15. Organ Recovery Systems Inc
• 16.16. Preservation Solutions Inc
• 16.17. Shanghai Genext Medical Technology Co.Ltd
• 16.18. Terumo Corporation
• 16.19. TransMedics Inc
• 16.20. Vascular Perfusion Solutions Inc
• 16.21. Waters Medical Systems LLC
• 16.22. XVIVO Perfusion AB